SCHEMBL2459339

SCHEMBL2459339

O=c1[nH]ncc2cc(Nc3ccccc3)c(Nc3ccccc3)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.51
▸ PRKCI P41743 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ PARP1 P09874 1/20 0.51
▸ PDE4B Q07343 1/20 0.51
▸ BRAF P15056 3/20 0.47
▸ MAPT P10636 3/20 0.45
▸ HPGD P15428 3/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ PRKD3 O94806 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ RGS12 O14924 1/20 0.45
▸ GMNN O75496 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ PRKCG P05129 1/20 0.45
▸ PRKCB P05771 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2462942 0.86 ALDH1A1 (0.44) ALDH1A1PRKCITDP1HSD17B10PARP1
SCHEMBL9413538 0.73 BRAF (0.76) ALDH1A1PRKCITDP1HSD17B10BRAF
SCHEMBL10577015 0.73 PKM (0.58) ALDH1A1PRKCITDP1MAPTHPGD
Phthalazinone SCHEMBL27602022 0.71 PARP1 (0.96) ALDH1A1PRKCITDP1HSD17B10PARP1
Phthalazinone SCHEMBL51553 0.69 PARP1 (1.00) ALDH1A1PRKCITDP1HSD17B10PARP1
SCHEMBL3766360 0.68 MAPT (0.64) ALDH1A1PRKCITDP1HSD17B10MAPT
SCHEMBL11577556 0.68 GLA (0.54) ALDH1A1TDP1HSD17B10MAPTHPGD
SCHEMBL25183266 0.68 ALDH1A1 (0.57) ALDH1A1PRKCITDP1HSD17B10PARP1
SCHEMBL30375279 0.68 ALDH1A1 (0.57) ALDH1A1PRKCITDP1HSD17B10PARP1
SCHEMBL9413547 0.68 ALDH1A1 (0.48) ALDH1A1PRKCITDP1HSD17B10PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044041-B2 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-10-25 — — US claimed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 — — US claimed
EP-0600831-A1 Phtalazinon derivatives CIBA-GEIGY AG (CH) 1994-06-08 — — EP claimed
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 — — US disclosed
US-8044041-B2 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-10-25 — — US disclosed
US-20110237571-A1 PHTHALAZINE DERIVATIVES ARALDI GIAN-LUCA 2011-09-29 — — US disclosed
US-7432263-B2 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PFIZER ITALIA, S.R.L. (IT) 2008-10-07 — — US disclosed
EP-1427708-B1 AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER ITALIA SRL (IT) 2008-09-10 — — EP disclosed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 — — US disclosed
US-20050020583-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PFIZER ITALIA S.R.L. (IT) 2005-01-27 — — US disclosed
US-20030073692-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them PHARMACIA & UPJOHN S.P.A. (IT) 2003-04-17 — — US disclosed
EP-0600831-A1 Phtalazinon derivatives CIBA-GEIGY AG (CH) 1994-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237571-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 ALDH1A1 3613/4885PRKCI 125/4885TDP1 2485/4885
US-20030073692-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them MAP3K20, MAP3K15, MAP3K5 ALDH1A1 4569/4885PRKCI 93/4885TDP1 1215/4885
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 ALDH1A1 3613/4885PRKCI 125/4885TDP1 2485/4885
US-20050020583-A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them MAP3K20, MAP3K1, MAP3K15 ALDH1A1 3566/4885PRKCI 199/4885TDP1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback